Status:
UNKNOWN
Anergia-anhedonia by Lithium-induced Phosphorus Diabetes
Lead Sponsor:
University Hospital, Strasbourg, France
Conditions:
Mood Disorders
Eligibility:
All Genders
18+ years
Brief Summary
Lithium (Li+) is prescribed to 1‰ of the French population (\~ 60,000 patients). More than half of patients describe subjective symptoms linked to Li+ (SSL) similar to those of chronic fatigue syndrom...
Detailed Description
The aim of the study is to determine the prevalence of hypophosphatemia, DPi and SSL in a population of ambulatory patients controlled on Li+ (\> 6 months).
Eligibility Criteria
Inclusion
- Major subject (≥ 18 years old)
- Man or woman
- Subject balanced on Li+ (\> 6 months, regardless of the underlying pathology).
- Outpatient monitoring by one of the members of CEDRA (Alsace expert center for resistant depression).
- Subject not opposing, after information, the reuse of their data for the purposes of this research
Exclusion
- Subject having expressed opposition to participating in the study
- Subject under judicial protection
- Subject under guardianship or curatorship
Key Trial Info
Start Date :
May 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 24 2024
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06111664
Start Date
May 1 2023
End Date
April 24 2024
Last Update
November 1 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CENTRE DE NEUROMODULATION NON INVASIVE DE STRASBOURG (CEMNIS) - CHU de Strasbourg - France
Strasbourg, France, 67091